Phlorizin attenuates chronic kidney disease induced bone loss by mitigating sclerostin mediated inhibition of Wnt/β-catenin signaling and ameliorating metabolic alterations.
- DOI
- 10.1016/j.biopha.2026.119810
- Published
- 2026 Oct
- Container
- Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.biopha.2026.119810,
title = {Phlorizin attenuates chronic kidney disease induced bone loss by mitigating sclerostin mediated inhibition of Wnt/β-catenin signaling and ameliorating metabolic alterations.},
author = {Rathur R and Ubaid M and Goswami A and Tomar MS and Srivastava S and Trivedi AK and Srivastava A and Srivastava KR and Singh D},
year = {2026},
journal = {Biomedicine \& pharmacotherapy = Biomedecine \& pharmacotherapie},
doi = {10.1016/j.biopha.2026.119810},
url = {https://doi.org/10.1016/j.biopha.2026.119810}
}RIS
TY - JOUR TI - Phlorizin attenuates chronic kidney disease induced bone loss by mitigating sclerostin mediated inhibition of Wnt/β-catenin signaling and ameliorating metabolic alterations. AU - Rathur R AU - Ubaid M AU - Goswami A AU - Tomar MS AU - Srivastava S AU - Trivedi AK AU - Srivastava A AU - Srivastava KR AU - Singh D PY - 2026 JO - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie DO - 10.1016/j.biopha.2026.119810 UR - https://doi.org/10.1016/j.biopha.2026.119810 ER -
APA
R, R., M, U., A, G., MS, T., S, S., AK, T., A, S., KR, S., & D, S. (2026). Phlorizin attenuates chronic kidney disease induced bone loss by mitigating sclerostin mediated inhibition of Wnt/β-catenin signaling and ameliorating metabolic alterations.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. https://doi.org/10.1016/j.biopha.2026.119810
Source records
- pubmed · retrieved 2026-09-25T23:54:33.597Z
- europe-pmc · retrieved 2026-09-25T23:54:33.609Z